WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTCBB:NNVC) (the “Company”) announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide™ anti-influenza therapeutics program. The Company is now developing certain additional information on NV-INF-1, with input from its FDA consultants, for the pre-IND application to the FDA. The Company is planning on two separate indications for NV-INF-1: High strength dosage form for hospitalized patients with severe influenza, and a single course therapy for the out-patients with less severe influenza.
